According to the CDC, no drugs are approved by the FDA for postexposure prophylaxis. Until recently, bebtelovimab was used for postexposure prophylaxis in patients at high risk for progression to severe COVID-19. Tixagevimab plus cilgavimab had been used for preexposure prophylaxis in individuals who were moderately to severely immunocompromised. Other monoclonal antibodies, including casirivimab/imdevimab and sotrovimab, were also previously used for postexposure prevention but are no longer used due to decreased efficacy against variants.
Learn more about COVID-2019.
This Rapid Review Quiz was excerpted and adapted from the Medscape articles Paxlovid Reduces Risk of COVID Death by 79% in Older Adults: Study; Nirmatrelvir/Ritonavir (Paxlovid); Is It COVID or Long COVID? Your Organs May Know; Coronavirus Resource Center; Coronavirus Disease 2019 (COVID-19) in Children; Long COVID Doubles Risk of Some Serious Outcomes in Children, Teens; Regular Physical Activity May Fight Infection, Illness From COVID: Study; Coronavirus Disease 2019 (COVID-19); COVID Smell Loss Tops Disease Severity as a Predictor of Long-term Cognitive Impairment; Sore Throat, Cough Now Top COVID Symptoms: UK Study; and COVID Skin Signs Vary by Type of Variant, UK Study Finds.
Image: Lukas Gojda/Dreamstime
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Rapid Review Quiz: COVID-19 Updates - Medscape - Sep 28, 2022.